Cor Vasa 2025, 67(4):535-540 | DOI: 10.33678/cor.2025.044

(Angiotensin II - mechanism of action, current evidence, and statement of the interdisciplinary working group on the use of angiotensin II in intensive care units)

Martin Balíka, Jan Benešb, Vladimír Černýc-h, Roman Kulach, Martin Matějoviči, Hynek Říhaj, Tomáš Tencerk
a Klinika anesteziologie, resuscitace a intenzivní medicíny, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze, Praha, Česká republika
b Klinika anesteziologie, resuscitace a intenzivní medicíny, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň, Plzeň, Česká republika
c Klinika anesteziologie, perioperační a intenzivní medicíny, Univerzita J. E. Purkyně v Ústí nad Labem a Masarykova nemocnice v Ústí nad Labem, Ústí nad Labem, Česká republika
d Národní institut kvality a excelence zdravotnictví, Praha, Česká republika
e Klinika anesteziologie a resuscitace, 3. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha, Česká republika
f Klinika anesteziologie, resuscitace a intenzivní medicíny, Lékařská fakulta v Hradci Králové, Univerzita Karlova v Praze a Fakultní nemocnice Hradec Králové, Hradec Králové, Česká republika
g Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, Canada
h Ústav klinických oborů a biomedicíny, Technická univerzita Liberec, Liberec, Česká republika
ch Klinika anesteziologie, resuscitace a intenzivní medicíny, Lékařská fakulta Ostravské univerzity a Fakultní nemocnice Ostrava, Ostrava, Česká republika
i I. interní klinika, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň, Plzeň, Česká republika
j Klinika anesteziologie a resuscitace, Kardiocentrum, Institut klinické a experimentální medicíny, Praha, Česká republika
k Klinika anesteziologie, resuscitace a intenzivní medicíny, 2. lékařská fakulta Univerzity Karlovy a Fakultní nemocnice v Motole, Praha, Česká republika

The medicinal product Giapreza containing angiotensin II for intravenous administration has been registered in the Czech Republic since 2023. Article describes the mechanism of action of the drug, summarizes current scientific evidence of its efficacy and safety, and presents opinion of the interdisciplinary working group on the use of angiotensin II in intensive care units, especially in patients with refractory vasoplegic shock. The text has been endorsed by the Czech Society of Intensive Medicine, the Czech Society of Anesthesiology and Intensive Medicine, and the Czech Association of Acute Cardiology.

Keywords: Angiotensin II, Angiotensin converting enzyme inhibitor, Extracorporeal circuit

Received: February 20, 2025; Revised: February 20, 2025; Accepted: March 16, 2025; Prepublished online: June 2, 2012; Published: October 6, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Balík M, Beneš J, Černý V, Kula R, Matějovič M, Říha H, Tencer T. (Angiotensin II - mechanism of action, current evidence, and statement of the interdisciplinary working group on the use of angiotensin II in intensive care units). Cor Vasa. 2025;67(4):535-540. doi: 10.33678/cor.2025.044.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Landoni G, Cortegiani A, Bignami E, et al. The use of angiotensin II for the management of distributive shock: expert consensus statements. J Anesth Analg Crit Care 2024;4:56. Go to original source...
    2. SUKL CMEC. decision on Giapreza 19.1.2023 [
    3. Xourgia E, Exadaktylos AK, Chalkias A, Ziaka M. Angiotensin II in the treatment of distributive shock: a systematic-review and meta-analysis. Shock 2024;62:155-164. Go to original source...
    4. Coulson TG, Miles LF, Zarbock A, et al. Renin-angiotensin-aldosterone system dynamics after targeted blood pressure control using angiotensin II or norepinephrine in cardiac surgery: mechanistic randomised controlled trial. Br J Anaesth 2023;131:664-672. Go to original source... Go to PubMed...
    5. Sadjadi M, von Groote T, Weiss R, et al. A Pilot Study of Renin-Guided Angiotensin-II Infusion to Reduce Kidney Stress After Cardiac Surgery. Anesth Analg 2024;139:165-173. Go to original source...
    6. Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 2017;377:419-430. Go to original source... Go to PubMed...
    7. Bellomo R, Zarbock A, Landoni G. Angiotensin II. Intensive Care Med 2024;50:279-282. Go to original source... Go to PubMed...
    8. Leisman DE, Privratsky JR, Lehman JR, et al. Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model. Proc Natl Acad Sci U S A 2022;119:e2211370119. Go to original source... Go to PubMed...
    9. Wieruszewski PM, Bellomo R, Busse LW, et al. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care 2023;27:175. Go to original source... Go to PubMed...
    10. Chawla LS, Russell JA, Bagshaw SM, et al. Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc 2017;19:43-49. Go to original source...
    11. Tumlin JA, Murugan R, Deane AM, et al. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med 2018;46:949-957. Go to original source... Go to PubMed...
    12. Bellomo R, Forni LG, Busse LW, et al. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial. Am J Respir Crit Care Med 2020;202:1253-1261. Go to original source...
    13. Chappell MC, Schaich CL, Busse LW, et al. Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial. Crit Care 2024;28:333. Go to original source... Go to PubMed...
    14. Eleuteri D, Montini L, Cutuli SL, et al. Renin-angiotensin system dysregulation in critically ill patients with acute respiratory distress syndrome due to COVID-19: a preliminary report. Crit Care 2021;25:91. Go to original source... Go to PubMed...
    15. Heinicke U, Adam E, Sonntagbauer M, et al. Angiotensin II treatment in COVID-19 patients: more risk than benefit? A single-center experience. Crit Care 2020;24:409. Go to original source... Go to PubMed...
    16. Busse LW, Wang XS, Chalikonda DM, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med 2017;45:1285-1294. Go to original source... Go to PubMed...
    17. Martin C, Medam S, Antonini F, et al. Norepinephrine: not too much, too long. Shock 2015;44:305-309. Go to original source... Go to PubMed...
    18. Legrand M, Khanna AK, Ostermann M, et al. The renin-angiotensin-aldosterone-system in sepsis and its clinical modulation with exogenous angiotensin II. Crit Care 2024;28:389. Go to original source...
    19. Ostermann M, Boldt DW, Harper MD, et al. Angiotensin in ECMO patients with refractory shock. Crit Care 2018;22:288. Go to original source... Go to PubMed...
    20. Levy B, Lescroart M, Combes A. Use of vasopressors and inotropes in ECMO. Intensive Care Med 2024;50:463-466. Go to original source... Go to PubMed...
    21. Busse LW, Barker N, Petersen C. Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options. Crit Care 2020;24:36. Go to original source... Go to PubMed...
    22. Bansal M, Mehta A, Wieruszewski PM, et al. Efficacy and safety of angiotensin II in cardiogenic shock: A systematic review. Am J Emerg Med 2023;66:124-128. Go to original source...
    23. Cutler NS, Rasmussen BM, Bredeck JF, et al. Angiotensin II for Critically Ill Patients With Shock After Heart Transplant. J Cardiothorac Vasc Anesth 2021;35:2756-2762. Go to original source... Go to PubMed...
    24. Wieruszewski PM, Radosevich MA, Kashani KB, et al. Synthetic Human Angiotensin II for Postcardiopulmonary Bypass Vasoplegic Shock. J Cardiothorac Vasc Anesth 2019;33:3080-3084. Go to original source... Go to PubMed...
    25. Jackson T, Corke C, Agar J. Enalapril overdose treated with angiotensin infusion. Lancet 1993;341:703. Go to original source...
    26. Newby DE, Lee MR, Gray AJ, Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II. Br J Clin Pharmacol 1995;40:103-104. Go to original source...
    27. Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. Ann Pharmacother 1994;28:1165-1168. Go to original source... Go to PubMed...
    28. Chen A, Wong A. The Role of Angiotensin II in Poisoning-Induced Shock-a Review. J Med Toxicol 2022;18:145-154. Go to original source... Go to PubMed...
    29. Lambden S, Creagh-Brown BC, Hunt J, et al. Definitions and pathophysiology of vasoplegic shock. Crit Care 2018;22:174. Go to original source...
    30. Ratnani I, Ochani RK, Shaikh A, Jatoi HN. Vasoplegia: A Review. Methodist Debakey Cardiovasc J 2023;19:38-47. Go to original source... Go to PubMed...
    31. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-887. Go to original source...
    32. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA 2016;316:509-518. Go to original source... Go to PubMed...
    33. Balik M, Novotny A, Suk D, et al. Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction. Cardiovasc Drugs Ther. 2020;34:685-688. Go to original source...
    34. Chawla LS, Busse L, Brasha-Mitchell E, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care 2014;18:534. Go to original source...
    35. Zangrillo A, Landoni G, Beretta L, et al. Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series. Crit Care 2020;24:227. Go to original source...
    36. Agency EM. EU Panel Backs Angiotensin II (Giapreza ) for Septic Shock 28.6.2019.
    37. Caragata R, Johnston SA, Chan JW, et al. Angiotensin-II and Thromboembolic Events: A Systematic Review. Crit Care Med 2024;52:1894-1905. Go to original source...
    38. Legrand M, Zarbock A. Ten tips to optimize vasopressors use in the critically ill patient with hypotension. Intensive Care Med 2022;48:736-739. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes